Compare CYTK & AOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | AOS |
|---|---|---|
| Founded | 1997 | 1874 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 8.6B |
| IPO Year | 2004 | 1994 |
| Metric | CYTK | AOS |
|---|---|---|
| Price | $76.84 | $63.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 9 |
| Target Price | ★ $89.26 | $75.44 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | N/A | ★ 6.06 |
| EPS | N/A | ★ 1.75 |
| Revenue | $13,368,000.00 | ★ $3,830,200,000.00 |
| Revenue This Year | $7.37 | $4.51 |
| Revenue Next Year | $310.19 | $3.80 |
| P/E Ratio | ★ N/A | $35.54 |
| Revenue Growth | N/A | ★ 0.32 |
| 52 Week Low | $34.60 | $54.16 |
| 52 Week High | $88.31 | $81.87 |
| Indicator | CYTK | AOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 57.68 |
| Support Level | $73.95 | $63.34 |
| Resistance Level | $79.66 | $63.91 |
| Average True Range (ATR) | 2.91 | 1.93 |
| MACD | -0.37 | 0.21 |
| Stochastic Oscillator | 33.77 | 78.84 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
A.O. Smith manufactures a broad lineup of water heaters, boilers, and water treatment products. The company has two reporting segments: North America (80% of sales) and rest of world (20% of sales). A.O. Smith is the leading manufacturer of water heaters in North America for the residential and commercial markets, with approximately 36% and 52% market share, respectively. Residential water heaters account for most of North American sales and are distributed equally through wholesale and retail channels. Most of A.O. Smith's international revenue is from China, a market the company entered in the mid-1990s.